This study material provides a comprehensive overview of Active Middle Ear Implants (AMEIs), covering their history, working principles, modern devices, candidacy criteria, and post-operative management. It consolidates information from a lecture recording and a provided text, aiming to offer a clear and structured learning experience.

---

📚 Active Middle Ear Implants (AMEIs): A Comprehensive Study Guide

1. Introduction to Active Middle Ear Implants (AMEIs)

According to the lecture recording and the provided text, while many patients with moderate to severe hearing loss can be treated with traditional hearing aids, some either do not benefit sufficiently or cannot use them due to anatomical issues or skin problems in the ear. Advances in medicine and technology have led to many new treatment options for various types and severities of hearing loss in recent years.

1.1. Classification of Implantable Hearing Devices

Implantable hearing devices can be broadly classified as:

• Bone Conduction Implants: Stimulate cochlear hair cells.
• Active Middle Ear Implants (AMEIs): Directly stimulate the ossicular chain, round window, or cochlea.
• Cochlear Implants: Stimulate neural structures.

1.2. Rationale for AMEI Development

Both sources highlight that bone conduction and active middle ear implantable hearing devices were primarily developed to address concerns that hindered the widespread adoption of traditional hearing aids. ✅ These devices bypass the external ear canal, eliminating issues related to:

• Suboptimal acoustics caused by the occlusion effect.
• Problems associated with chronic otitis.

Additionally, implantable hearing devices that directly stimulate the cochlea by attaching to the incus, stapes superstructure, basal plate, or round window membrane have the potential to:

• Overcome gain limitations.
• Resolve acoustic issues related to distortion, feedback, and high output levels.

📚 Definition: According to both sources, implantable hearing devices are devices with a surgically placed component that replaces the receiver of a traditional hearing aid and directly stimulates the ossicular chain, round window, or cochlea. The term "active middle ear implant" refers to the implanted component but is often used to describe the entire device. The final component that energizes the hearing system for all implantable hearing devices is a mechanical transducer, either piezoelectric or electromagnetic-based.

---

2. Historical Development of Active Middle Ear Implants

The history of AMEIs spans several decades, marked by innovations in transducer technology and surgical approaches.

2.1. Early Electromagnetic Transducers

According to the lecture recording and the provided text:

• 1935 (Alvar Wilska, Finland): Conducted early experiments by placing iron particles on subjects' eardrums and creating an oscillating magnetic field with a small electromagnetic coil in the ear canal.
• 1959 (Rutschmann, New York): Performed a similar experiment, attaching small magnets to the malleus bone of patients and passing current through a coil in the external ear canal. Subjects successfully perceived tones from 2 to 10 kHz.

2.2. Early Implantable Electromagnetic Devices

The provided text details further developments:

• 1986 (Case Western Reserve University): Researchers began investigating various prototypes of implantable electromagnetic hearing devices. They settled on a contactless device where the magnetic implant was placed on the incus and physically separated from the driving induction coil.
  • This device was known as the Semi-Implantable Middle Ear Electromagnetic Hearing Device (SIMEHD system).
  • Although FDA approval for clinical trials was granted in 1996, no further data on this device was published.
• Michigan Ear Institute & Smith & Nephew Richards Company: Developed a second set of similar devices.
  • Phase I: A small target magnet (Electromagnetic Ossicular Augmentation Device, EOAD) was temporarily attached to the lateral surface of the eardrum in patients with sensorineural hearing loss.
  • Phase II: The target magnet was incorporated into an ossicular chain prosthesis (Electromagnetic Ossicular Replacement Device, EORD) for patients with mixed hearing loss.
  • Phase III: Involved the implantation of the EOAD on the lateral surface of the eardrum in patients with sensorineural hearing loss.
  • These devices were driven by an electromagnetic coil placed in a custom mold, similar to an in-the-ear hearing aid.
  • ⚠️ Despite promising initial results, the company eventually lost funding, and the device is no longer in use.

2.3. Direct Acoustic Cochlear Stimulator (DACS)

According to the provided text:

• Developed through a collaboration between Cochlear and Phonak Acoustic Implants as a powered stapes prosthesis.
• Designed for treating moderate to severe mixed hearing loss, primarily for advanced otosclerosis.
• Original Design: An electromechanical DACS transducer connected to a conventionally placed stapes prosthesis, driven by an external auditory processor fixed with a percutaneous plug.
• DACS-PI (Partial Implant) System: Phonak Acoustic Implants refined the original design, using a similar electromagnetic transducer but replacing the percutaneous processor with a magnetically coupled button device.
• ⚠️ While showing promising results for otosclerosis patients with advanced to profound mixed hearing loss, only a few studies were published, none reporting long-term outcomes, and the continuous availability of this device was questionable.

2.4. Cochlear Carina (Original MET System)

The provided text explains:

• Development began in the 1970s at Washington University in St. Louis as a partially implantable electromagnetic transducer.
• Initially known as the Middle Ear Transducer (MET) Ossicular Stimulator.
• Exhibited promising characteristics in its relatively linear input-output function.
• Original Otologics MET system: Consisted of an implanted electromagnetic transducer mounted on a titanium bracket attached to the mastoid, and an external button processor for transcutaneous electrical signal and internal device power.
• Fully Implantable Carina: Combined external and internal components into a single device, designed as a rechargeable battery, digital signal processor, microphone, transducer, magnet, and receiver coil.
• Implantation: Initially designed to connect to the body of the incus, requiring a cortical mastoidectomy and atticotomy approach. Later developments allowed for alternative attachment locations (e.g., stapes) and different actuator terminals.
• ⚠️ The technology was sold to Otologics, and while Phase 1 clinical trials in the US were not completed, the device was approved for use in Europe and South America. The fully implantable system, known as Carina, received the EU CE mark in 2006 for sensorineural hearing loss and in 2007 for mixed hearing loss. Cochlear Corporation later acquired Carina, but its distribution was halted in May 2020 due to its potential to harm patients with severe mixed or sensorineural hearing loss.

2.5. Piezoelectric Transducers

According to the provided text:

• Piezoelectric principles were described much earlier in the 19th century by Jacques and Pierre Curie, who noted that certain solids develop an electrical charge under mechanical stress and deform when an electric current is applied.
• This led to the idea that small crystals could be used in middle ear implants to drive the ossicular chain with predictable micro-oscillations.
• Late 1970s (Japan): Researchers developed the RION device, a piezoelectric middle ear implant. A fully implantable version was successfully tested in cats, and a partially implantable device began human clinical trials in 1984, approved for commercial use in 1993.
  • ⚠️ Despite good hearing outcomes for most patients, the device was discontinued in 2005 due to limited and insufficient reimbursement in the Japanese socialized medical system.
• Early 1990s (Germany): The first fully implantable piezoelectric middle ear implant, the Totally Implantable Cochlear Amplifier (TICA LZ3001), was developed.
  • It received the EU CE Mark in 1998, becoming the first approved fully implantable middle ear device.
  • Components: membranous sound sensor, piezoelectric transducer, and internal processor (housing the battery).
  • The implant battery was rechargeable via an induction coil.
  • ⚠️ While 17 out of 20 subjects in Phase 3 clinical trials showed improvement in speech recognition and localization, the company developing the device went bankrupt. Cochlear Corporation acquired the intellectual property rights but did not bring it to the commercial market for implantation.

---

3. Working Principles of AMEI Transducers

Modern AMEIs typically incorporate one of three different transducer types, as detailed in the provided text:

3.1. Piezoelectric Transducers

📚 Principle: Piezoelectric materials have a unique property:

• When a voltage is applied, the crystal oscillates, transmitting mechanical energy to the middle ear structure it's connected to.
• When physically displaced (moved back and forth), they generate an electrical voltage. ✅ Advantages:
• Do not require a power source to convert mechanical-acoustic signals to electrical signals.
• Relatively robust stability and durability.
• Examples: Lead Zirconate Titanate (PZT), barium titanate, quartz, Rochelle salt (PZT is commonly used in AMEIs). ⚠️ Disadvantages:
• Relatively low output and narrow bandwidth compared to electromagnetic and electromechanical transducers.
• May not provide sufficient amplification for recipients with moderate-to-severe to severe hearing loss.

3.2. Electromagnetic Transducers

📚 Principle:

• Involve a biocompatible magnet attached to the ossicular chain (or another middle ear structure) and positioned near a wired coil.
• An electric current transmitted to the coil creates an oscillating magnetic field, which alternately attracts and repels the magnet, causing it to oscillate.
• The mechanical energy from the magnet's oscillation is transmitted to the ossicular chain. ✅ Advantages:
• Widely used in electronic applications and can successfully transmit audio signals across the speech frequency bandwidth. ⚠️ Disadvantages:
• Output depends on the magnet's proximity to the stimulating coil. Output decreases by the square of the distance between the coil and the magnet.
• Head and mouth movements can temporarily alter the distance, leading to instantaneous changes in output.

3.3. Electromechanical Transducers

📚 Principle:

• A variation of electromagnetic transducers designed to overcome the limitation of suboptimal distance between the coil and magnet.
• Consist of a biocompatible magnet surrounded by a wire coil, meaning the coil and magnet are integrated into a single package, optimizing and fixing their spatial separation.
• The electromechanical transducer is physically attached to the ossicular chain (or round window).
• An electric current from the AMEI's processor is transmitted to the coil, creating an electromagnetic field that alternately attracts and repels the underlying magnet.
• The mechanical energy from the oscillating magnet is transmitted to the attached structure. ✅ Advantages:
• Potential for higher output levels and wider frequency response.
• Not prone to variable outputs when the distance between the magnet and coil changes. ⚠️ Disadvantages:
• Theoretically, using multiple components in a single package could create a more complex device prone to mechanical failure. However, modern manufacturing practices have significantly reduced this potential limitation.

---

4. Modern Active Middle Ear Implant Systems

Several companies have developed AMEIs, with some currently undergoing clinical trials and others commercially available. According to the provided text and lecture recording, the following are prominent examples:

4.1. MED-EL Vibrant SoundBridge (VORP 503)

✅ FDA Approved: Widely used in the US and Europe. 1️⃣ Components:

• Receiver coil surrounding a biocompatible magnet.
• Internal processor and stimulator.
• Cable transmitting electrical current from the transducer to the stimulator.
• Floating Mass Transducer (FMT). ✅ Key Features:
• MRI Compatibility: MED-EL suggests the VORP 503 is compatible with 1.5-T MRI because the poles of the magnets are designed to react neutrally to the MRI's magnetic field, preventing alignment.
• Lower profile than previous models.
• Includes two "fixation holes" for titanium screws to enhance stability of the receiver coil and stimulator.
• Provides a range of couplers (e.g., short incus process, long incus process, stapes head, round window) allowing the surgeon to optimize attachment to the desired location.
  • Incus LP Coupler: Often preferred for SNIK treatment. Easily placed on the long arm of the incus without clamping or screwing.
  • Incus SP Coupler: Newer, placed via posterior epitympanotomy, away from the facial nerve and chorda tympani. Sits on the short arm of the incus.
  • Round Window Soft Coupler: Used for conductive or mixed hearing loss. Anatomically optimized, requires less drilling than coupler-less round window vibroplasty. Stabilized with cartilage behind the transducer.
  • Vibroplasty-Clip Coupler: Placed on the head/neck region of the stapes. 📚 Sound Processor: Uses the SAMBA 2 sound processor. 📊 Indications (According to the provided text):
• Adults (18 years and older).
• Audiological results consistent with sensorineural hearing loss.
• Unaided pure-tone air conduction thresholds within specific ranges:
  • 500 Hz: 30–65 dB HL
  • 1000 Hz: 40–75 dB HL
  • 1500 Hz: 45–80 dB HL
  • 2000 Hz: 45–80 dB HL
  • 3000 Hz: 50–85 dB HL
  • 4000 Hz: 50–85 dB HL
• Word recognition of 50% or better in the best aided condition (65 dB SPL presentation level) or under headphones at the most comfortable listening level.
• Normal middle ear anatomy. ⚠️ Contraindications (According to the provided text):
• Conductive hearing loss.
• Retrocochlear or central auditory disorder.
• Active middle ear infections.
• Tympanic membrane perforations associated with recurrent middle ear infections.
• Skin or scalp condition that would prevent sound processor placement. 💡 Programming: Uses NOAH HI-PRO and NOAHLink interfaces. Initial settings are based on evidence-based methods (DSL-I/O, NAL-NL1, NAL-NL2). Fine-tuning allows adjustments to gain/output, compression, microphone mode, noise reduction, etc. A "Vibrogram" feature measures in-situ thresholds to determine individualized gain/output.

4.2. Ototronix MAXUM System

✅ FDA Approved: Widely used in the US and Europe. 1️⃣ Components:

• Externally worn ear-level sound processor (Integrated Processor and Coil - IPC).
• Neodymium-iron-boron magnet housed in a titanium casing, surgically implanted. 📚 Working Principle:
• The IPC (worn in the ear canal) contains a microphone, digital signal processor, and an electromagnetic coil.
• The microphone captures sound, the DSP analyzes it, and converts it into an electrical current for the electromagnetic coil.
• The electromagnetic field generated by the coil propagates through the tympanic membrane towards the MAXUM magnet, which is attached to the incudostapedial joint at the stapes neck.
• This field alternately repels and attracts the magnet, causing it to oscillate and provide mechanical energy to the ossicular chain.
• ⚠️ Deep placement of the IPC in the ear canal is crucial for optimal performance. 📊 Indications (FDA, according to the provided text):
• Adults (18 years and older).
• Moderate to severe sensorineural hearing loss (SNIK). ⚠️ Contraindications (According to the provided text):
• Conductive hearing loss.
• Retrocochlear or central auditory disorder.
• Active middle ear infections.
• Tympanic membrane perforations associated with recurrent middle ear infections.

4.3. Envoy Esteem

✅ FDA Approved: The only fully implantable hearing device approved for commercial distribution by the FDA. 1️⃣ Components (All implanted in the temporal bone):

• Esteem Sensor (piezoelectric transducer attached to the incus body).
• Esteem Sound Processor.
• Esteem Driver (piezoelectric transducer attached to the head of the stapes bone).
• Non-rechargeable lithium-iodide battery. 📚 Working Principle:
• The Esteem Sound Processor and battery are implanted in a "bed" carved into the temporal bone behind the auricle. The sensor and driver are placed in the middle ear cavity.
• The Esteem Sensor captures incus movement and converts it into an electrical signal, which is transmitted to the Esteem Sound Processor.
• The processed signal is then sent to the Esteem Driver, which converts the electrical signal back into mechanical oscillations.
• The mechanical energy from the oscillating driver is transmitted back to the ossicular chain.
• ⚠️ To avoid a feedback loop between the sensor and driver, the surgeon must disarticulate the ossicular joints between the incus and stapes. This results in a conductive hearing loss post-surgery when the device is off.
• Battery Life: Predicted to last 4.5 to 9 years, but can be as short as 2.8 years for individuals exposed to consistently high sound levels. The battery and sound processor can be replaced under local or general anesthesia. ⚠️ MRI Compatibility: Not MRI compatible. Individuals requiring serial MRI evaluations should not consider this device. 📊 Indications (FDA, according to the provided text):
• Adults (18 years and older).
• Stable bilateral moderate to severe sensorineural hearing loss (SNIK).
• Unaided speech discrimination scores of 40% or better.
• Normal middle ear anatomy and function.
• Sufficient space in the middle ear for the Esteem implant, confirmed by high-resolution CT.
• Failure to benefit from at least 30 days of trial with appropriate hearing aid fitting. ⚠️ Contraindications (According to the provided text):
• History of chronic middle ear infections post-adolescence, inner ear disorders, or conditions requiring treatment for recurrent vertigo, mastoiditis, hydrops, or Meniere's syndrome/disease.
• Known history of fluctuating air conduction and/or bone conduction hearing loss of 15 dB in two or more frequencies between 500 and 4000 Hz in either direction within the past year.
• History of otitis externa or eczema in the external auditory canal.
• Cholesteatoma or destructive middle ear disease.
• Retrocochlear or central auditory disorder.
• Disabling tinnitus (as defined by tinnitus requiring treatment).
• History of keloid formation.
• Hypersensitivity to silicone rubber, polyurethane, stainless steel, titanium, and/or gold.
• Pre-existing medical condition or treatment that could affect the healing process.
• Pregnancy. 💡 Post-operative Management Tools:
• Esteem Intraoperative System Analyzer: Evaluates implant function intra- and post-operatively (e.g., transducer operation, feedback loop presence).
• Esteem Programmer: Used by audiologists to program the implant.
• Esteem Personal Programmer: A remote control for the user to adjust volume, change programs, and put the device in standby mode (to conserve battery life).
• Activation typically occurs 6-8 weeks post-surgery. Optimal performance is usually achieved 4-6 months post-surgery.

4.4. Otologics Carina (Acquired by Cochlear)

According to the provided text:

• Did not receive FDA approval.
• Distribution was halted by Cochlear Corporation in May 2020. 1️⃣ Components (Fully implantable):
• Receiver coil surrounding a biocompatible magnet.
• Microphone placed subcutaneously above and behind the auricle.
• Digital signal processor.
• Rechargeable battery.
• Electromechanical transducer connected via an IS-1 connector. 📚 Working Principle:
• The electromechanical transducer operates in a piston-like manner when stimulated, connecting to a hole drilled by the surgeon in the long process of the incus.
• The implanted microphone captures sound, converts it to an electrical signal, and sends it to the DSP for analysis.
• The processed electrical signal is then transmitted to the electromechanical transducer, whose oscillating, piston-like motion transmits mechanical energy to the ossicular chain.
• The rechargeable battery is charged externally via a charging coil placed on the head over the implant's receiver coil. Designed for a full day's use per charge and a lifespan of up to eight years.
• When the battery expires or the processor fails, the battery and receiver coil can be removed from the IS-1 connector, leaving the electromechanical transducer in place.

4.5. CODACS Direct Acoustics Cochlear Stimulation (DACS)

According to the provided text:

• A partially implantable device designed for individuals with advanced to profound mixed hearing loss caused by otosclerosis.
• Currently not FDA approved, but Cochlear has CE mark approval for DACS in Europe. 1️⃣ Components:
• External ear-level sound processor with a transmitting coil surrounding a magnet.
• Internal receiver coil surrounding a magnet.
• Digital signal processor/stimulator.
• Electromechanical transducer (actuator).
• Middle ear ossicular prosthesis. 📚 Working Principle:
• Sound signals are captured by the sound processor's microphones, sent to the DSP for analysis, and then transmitted to the external coil.
• The internal receiver coil receives the signal, converts it to an electrical signal, and sends it to the implant's processor, which then drives the transducer.
• The transducer's oscillation transmits mechanical energy to the middle ear prosthesis or directly to the round window.
• DACS is considered a potentially beneficial solution for individuals with severe otosclerosis and residual cochlear function, providing satisfactory speech recognition with adequate stimulation.

---

5. Candidacy Criteria for Active Middle Ear Implants

According to the lecture recording and the provided text, evaluating candidacy for AMEIs is a comprehensive process.

5.1. General Candidacy

• Age: Generally considered for adults (18 years and older).
• Hearing Loss Type: Primarily for sensorineural hearing loss (SNIK).
• Severity: Ideal candidates typically have moderate to moderate-severe hearing loss.
  • ⚠️ Individuals with mild hearing loss are unlikely to undergo the expensive cost and invasive surgery.
  • ⚠️ Individuals with severe to profound hearing loss (pure-tone thresholds 75-80 dB HL or worse) are generally better candidates for cochlear implants, as the severity of loss may limit the benefit from AMEIs.
• Speech Understanding: Ideal candidates have good speech understanding scores.
  • ⚠️ Those with low speech understanding scores (less than 60% in optimal conditions) are not ideal candidates, as their limited speech recognition capacity (possibly due to cochlear dysfunction or auditory processing deficits) would restrict the AMEI's performance.

5.2. Specific Considerations for Conductive/Mixed Hearing Loss

• Chronic Conductive Hearing Loss: Historically considered poor candidates.
  • ⚠️ Chronic middle ear effusion is a contraindication, as fluid would impede the mechanical oscillation of the transducer.
• Potential for AMEIs: However, AMEIs can be considered for some adults with conductive hearing loss, provided the middle ear cavity is aerated and there is no threat of chronic middle ear effusion or cholesteatoma.
  • For example, some AMEI transducers can be attached to the round window instead of the ossicular chain, effectively bypassing the middle ear and providing direct stimulation to the cochlea. This approach may be ideal for candidates with otosclerosis or other ossicular chain pathologies.

5.3. Pre-Operative Assessment

The assessment sequence for AMEI candidacy should include:

• Audiometry: Air and bone conduction pure-tone audiometry at octave and inter-octave frequencies from 250 to 8000 Hz.
• Middle Ear Measurements: Tympanometry, acoustic reflex threshold assessment, and wideband reflectance to evaluate the conductive properties of the middle ear system.
• Hearing Aid Trial: The candidate must have completed a trial with the most appropriate traditional air conduction hearing aids to meet their needs. Gains should be verified with Real-Ear Measurements (REM) to confirm optimal output.
• Medical Evaluation: A comprehensive medical evaluation by an otologist to ensure the candidate meets otological and medical criteria.
• Imaging:
  • Typically, a CT scan is requested to assess middle ear anatomy.
  • Some otologists may request an MRI to evaluate the central nervous system pre-operatively, as the presence of a middle ear implant can complicate post-operative MRI interpretation.

5.4. Turkish Social Security Institution (SUT) Criteria (2024)

According to the provided text, the cost of middle ear implants is covered by the institution for patients meeting specific criteria, as determined by a health board report from three ENT specialists and an audiologist from the same official healthcare provider. Hearing thresholds must be stable for the last two years.

📊 a) Sensorineural Hearing Loss:

1. Sensorineural hearing loss not exceeding 65 dB at 500 Hz, 70 dB at 1000 and 2000 Hz, and 85 dB at 4000 Hz.
2. Speech discrimination score better than 50%.
3. Health board report must state the absence of retrocochlear pathology.

📊 b) Conductive and Mixed Hearing Loss:

1. Mixed or conductive hearing loss with bone conduction thresholds not worse than 60 dB.
2. Speech discrimination score better than 50%.
3. Health board report must state that the patient's hearing loss in both ears could not be corrected despite having undergone at least one prior surgery.

📊 c) Special Conditions for Bilateral Hearing Loss (No conventional hearing aid correction required):

1. Patients with bilateral radical mastoidectomy cavities resulting from previous ear surgery.
2. Patients with bilateral congenital external and middle ear anomalies.
3. Healthcare professionals who require the use of a stethoscope and have a hearing aid indication.

---

6. Post-Operative Management

According to the lecture recording and the provided text, post-operative management is crucial for successful AMEI outcomes.

6.1. Healing and Activation

• Healing Period: Typically, several weeks pass between AMEI surgery and device activation.
• Otologist's Role: The otologist must examine the implant site for signs of inflammation or distress.
• Audiologist's Role: The audiologist uses the manufacturer's proprietary software and devices to program the AMEI.

6.2. Device Programming and Verification

• ⚠️ Unlike traditional air conduction hearing aids, there is no standard verification measure (like REM) to assess AMEI output against an evidence-based prescriptive rule.
• Behavioral Assessment: Audiologists must complete behavioral assessments to determine if the user is receiving adequate benefit and achieving satisfactory hearing performance.
  • Free-Field Pure-Tone Thresholds: Should be measured and the device programmed to optimize audibility for low-level sounds. Ideally, free-field thresholds should be in the 20-30 dB HL range, though for individuals with moderate-to-severe hearing loss, achieving thresholds better than 30 dB HL may not be possible.
  • Speech Recognition Assessment: Recommended to evaluate aided monosyllabic word recognition at 50 and 60 dB HL in free field. Programming adjustments should optimize aided speech recognition for low and mid-level speech inputs.
  • Sentence Recognition in Noise: Evaluation of sentence recognition in noise is also a measure of speech understanding performance. This helps determine if additional assistance is needed (e.g., counseling on communication strategies, use of directional microphones, assistive listening technology).
  • Standardized Questionnaires: Audiologists should administer standardized questionnaires (e.g., APHAB, COSI) to assess the user's daily hearing performance with the implant.

---

7. Advantages and Disadvantages of AMEIs

Both sources discuss the theoretical advantages and practical disadvantages of AMEIs.

7.1. Theoretical Advantages (Historically)

In the 1990s and early 2000s, AMEIs were seen as a solution to limitations of analog and older digital hearing aids. ✅ According to the provided text, these include:

• Increased Usable Gain without Acoustic Feedback: While the threat of acoustic feedback is reduced, it's not entirely eliminated. Increased mechanical oscillation of middle ear structures can leak acoustic or mechanical energy back to the implant's microphone/sensor, causing an oscillatory feedback loop.
• Prevention of Occlusion Effect: By bypassing the ear canal. It's important to note that AMEIs not requiring a component in the ear canal may be the only suitable option for individuals with chronic otitis externa or severe skin allergies. They are also not prone to issues from earwax.
• Greater Comfort: Although some devices still require a component on or in the ear, many commercial devices require at least a head-worn component.
• **Higher Quality Sound with …